Showing results (301-310 of 326) with videos related to
Sort By:
Pageof 33
The Lancet. Respiratory Medicine|September 6, 2025
Sweat chloride and lung function responses to elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studiesPierre-Régis Burgel, Jennifer Da Silva, Emmanuelle Girodon, et al.Biorxiv : the Preprint Server for Biology|August 8, 2025
CSF1R regulates monocyte subset differentiation and intracellular metabolismAlexandre Gallerand, Johanna Merlin, Zakariya Caillot, et al.Toxicological Sciences : an Official Journal of the Society of Toxicology|April 3, 2014
Phenobarbital induces cell cycle transcriptional responses in mouse liver humanized for constitutive androstane and pregnane x receptorsRaphaëlle Luisier, Harri Lempiäinen, Nina Scherbichler, et al.American Journal of Hematology|January 4, 2022
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitorsYazan Numan, Zaid Abdel Rahman, Justin Grenet, et al.The Lancet. Respiratory Medicine|August 16, 2024
The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world studyPierre-Régis Burgel, Isabelle Sermet-Gaudelus, Emmanuelle Girodon, et al.Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|May 11, 2024
Exclusive oral antibiotic treatment for hospitalized community-acquired pneumonia: a post-hoc analysis of a randomized clinical trialAurélien Dinh, Clara Duran, Jacques Ropers, et al.JAMA Network Open|October 15, 2021
Factors Associated With Treatment Failure in Moderately Severe Community-Acquired Pneumonia: A Secondary Analysis of a Randomized Clinical TrialAurélien Dinh, Clara Duran, Jacques Ropers, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 25, 2025
First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: Report from the MODUL-CF studyAnne-Sophie Bonnel, Tiphaine Bihouée, Mélanie Ribault, et al.Lancet (London, England)|March 28, 2021
Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trialAurélien Dinh, Jacques Ropers, Clara Duran, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|July 8, 2023
Nonsense mutations accelerate lung disease and decrease survival of cystic fibrosis childrenAnnalisa Orenti, Iwona Pranke, Caroline Faucon, et al.Pageof 33